Heterotricyclic himbacine analogs as potent, orally active thrombin receptor (protease activated receptor-1) antagonists

Journal of Medicinal Chemistry

Volumn 50, Issue 21, 2007, Pages 5147-5160

  Chelliah, Mariappan V ^a   Chackalamannil, Samuel ^a   Xia, Yan ^a   Eagen, Keith ^a   Clasby, Martin C ^a   Gao, Xiaobang ^a   Greenlee, William ^a   Ahn, Ho Sam ^a   Agans Fantuzzi, Jacqueline ^a   Boykow, George ^a   Hsieh, Yunsheng ^a   Bryant, Matthew ^a   Palamanda, Jairam ^a   Chan, Tze Ming ^a   Hesk, David ^a   Chintala, Madhu ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DECAHYDRO 1 METHYL 3 OXO 9 [2 [5 (3 FLUOROPHENYL) 2 PYRIDINYL]ETHENYL] FURO[3,4 G]ISOQUINOLINE 6(3H) CARBOXYLIC ACID ETHYL ESTER; HIMBACINE; PROTEINASE ACTIVATED RECEPTOR 1; THROMBIN RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CHEMICAL MODIFICATION; CHEMICAL REACTION; DRUG STRUCTURE; DRUG SYNTHESIS; EX VIVO STUDY; MONKEY; NONHUMAN; RECEPTOR AFFINITY; THROMBOCYTE AGGREGATION INHIBITION;

ADMINISTRATION, ORAL; ALKALOIDS; ANIMALS; BIOLOGICAL AVAILABILITY; BLOOD PLATELETS; FURANS; HETEROCYCLIC COMPOUNDS, 3-RING; HUMANS; ISOQUINOLINES; MACACA FASCICULARIS; MICE; MICROSOMES, LIVER; NAPHTHALENES; PIPERIDINES; PLATELET AGGREGATION INHIBITORS; PYRIDINES; RATS; RECEPTOR, PAR-1; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 35348867494     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm070704k     Document Type: Article

References (37)

1. Davie, E. W.; Fujikawa, K.; Kisiel, W. The coagulation cascade: Initiation, maintenance, and regulation. Biochemistry 1991, 30, 10363-10370.
2. Reiter, R. A.; Jilma, B. Platelets and new antiplatelet drugs. Therapy 2005, 2 (3), 465-502.
3. Volturo, G. A.; Mazzola, J. L.; Przyklenk, K. The role of antiplatelet therapy in the management of acute coronary syndromes. Expert Opin. Drug Saf. 2005, 4 (3), 541-556.
4. Jackson, S. P.; Schoenwaelder, S. M. Antiplatelet therapy: In search of the "magic bullet". Nat. Rev. Drug Discovery 2003, 2 (10), 775-789.
5. Bhatt, D. L.; Topol, E. J. Scientific and therapeutic advances in antiplatelet therapy. Nat. Rev. Drug Discovery 2003, 2, 15-28.
6. Newby, L. K.; Califf, R. M.; White, H. D.; Harrington, R. A.; Van de Werf, F.; Granger, C. B.; Simes, R. J.; Hasselblad, V.; Armstrong, P. W. The failure of orally administered glycoprotein IIb/IIIa inhibitors to prevent recurrent cardiac events. Am. J. Med. 2002, 112 (8), 647-658.
7. Coughlin, S. R. Protease-activated receptors. In Handbook of Cell Signaling; Bradshaw, R. A., Dennis, E. A., Eds.; Elsevier: San Diego, CA, 2004; Vol. 1, pp 167-171.
8. Coughlin, S. R. Protease-activated receptors in the cardiovascular system. Cold Spring Harbor Symp. Quant. Biol. 2002, 67, 197-208.
9. Coughlin, S. R. Protease-activated receptors in vascular biology. Thromb. Haemostasis 2001, 86, 298-307.
10. Chackalamannil, S. Thrombin receptor (protease activated receptor-1) antagonists as potent antithrombotic agents with strong antiplatelet effects. J. Med. Chem. 2006, 49, 5389-5403.
11. Grand, R. J. A.; Turnell, A. S.; Grabham, P. W. Cellular consequences of thrombin-receptor activation. Biochem. J. 1996, 313, 353-368.
12. Coughlin, S. R. Protease-activated receptors in hemostasis, thrombosis, and vascular biology. J. Thromb. Haemostasis. 2005, 3, 1800-1814.
13. Coughlin, S. R. How the protease thrombin talks to cells. Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 11023-11027.
14. Vu, T.-K. H.; Hung, D. T.; Wheaton, V. I.; Coughlin, S. R. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell 1991, 64, 1057-1068.
15. Hung, D. T.; Vu, T.-H.; Nelken, N. A.; Coughlin, S. R. Thrombin-induced events in non-platelet cells are mediated by the unique proteolytic mechanism established for the cloned platelet thrombin receptor. J. Cell Biol. 1992, 116, 827-832.
16. Vu, T.-K. H.; Wheaton, V. I.; Hung, D. T.; Charo, I.; Coughlin, S. R. Domains specifying thrombin-receptor interaction. Nature 1991, 353, 674-677.
17. Chackalamannil, S.; Xia, Y.; Greenlee, W. J.; Clasby, M.; Doller, D.; Tsai, H.; Asberom, T.; Czarniecki, M.; Ahn, H.-S.; Boykow, G.; Foster, C.; Agans-Fantuzzi, J.; Bryant, M.; Lau, J.; Chintala, M. Discovery of potent orally active thrombin receptor (protease activated receptor 1) antagonists as novel antithrombotic agents. J. Med. Chem. 2005, 48, 5884-5887.
18. Clasby, M. C.; Chackalamannil, S.; Czarniecki, M.; Doller, D.; Eagen, K.; Greenlee, W.; Kao, G.; Lin, Y.; Tsai, H.; Xia, Y.; Ahn, H.-S.; Agans-Fantuzzi, J.; Boykow, G.; Chintala, M.; Foster, C.; Smith-Torhan, A.; Alton, K.; Bryant, M.; Hsieh, Y.; Lau, J.; Palamanda, J. Metabolism-based identification of a potent thrombin receptor antagonist. J. Med. Chem. 2007, 50, 129-138.
19. Andrade-Gordon, P.; Maryanoff, B. E.; Derian, C. K.; Zhang, H.-C.; Addo, M. F.; Darrow, A. L.; Eckardt, A. J.; Hoekstra, W. J.; McComsey, D. F.; Oksenberg, D.; Reynolds, E. E.; Santulli, R. J.; Scarborough, R. M.; Smith, C. E.; White, K. B. Design, synthesis, and biological characterization of a peptide-mimetic antagonist for a tethered-ligand receptor. Proc. Natl. Acad. Sci. U.S.A. 1999, 96 (22), 12257-12262.
20. Zhang, H.-C.; Derian, C. K.; Andrade-Gordon, P.; Hoekstra, W. J.; McComsey, D. F.; White, K. B.; Poulter, B. L.; Addo, M. F.; Cheung, W.-M.; Damiano, B. P.; Oksenberg, D.; Reynolds, E. E.; Pandey, A.; Scarborough, R. M.; Maryanoff, B. E. Discovery and optimization of a novel series of thrombin receptor (PAR-1) antagonists: Potent, selective peptide mimetics based on indole and indazole templates. J. Med. Chem. 2001, 44 (7), 1021-1024.
21. Zhang, H.-C.; White, K. B.; McComsey, D. F.; Addo, M. F.; Andrade-Gordon, P.; Derian, C. K.; Oksenberg, D.; Maryanoff, B. E. High-affinity thrombin receptor (PAR-1) ligands: A new generation of indole - Based peptide mimetic antagonists with a basic amine at the C-terminus. Bioorg. Med. Chem. Lett. 2003, 13 (13), 2199-2203.
22. Ahn, H.-S.; Arik, L.; Boykow, G.; Burnett, D. A.; Caplen, M. A.; Czarniecki, M.; Domalski, M. S.; Foster, C.; Manna, M.; Stamford, A. W.; Wu, Y. Structure-activity relationships of pyrroloquinazolines as thrombin receptor antagonists. Bioorg. Med. Chem. Lett. 1999, 9 (14), 2073-2078.
23. Ahn, H.-S.; Foster, C.; Boykow, G.; Stamford, A.; Manna, M.; Graziano, M. Inhibition of cellular action of thrombin by N3-cyclopropyl-7-{[4-(1- methylethyl)phenyl]methyl}-7H-pyrrolo[3,2-f]-quinazoline-1, 3-diamine (SCH 79797), a nonpeptide thrombin receptor antagonist. Biochem. Pharmacol. 2000, 60 (10), 1425-1434.
24. Chackalamannil, S.; Doller, D.; Eagen, K.; Czarniecki, M.; Ahn, H. S.; Foster, C. J.; Boykow, G. Potent, low molecular weight thrombin receptor antagonists. Bioorg. Med. Chem. Lett. 2001, 77, 2851-2853.
25. After intravenous administration of a radiolabeled sample of 2 in cynomolgus monkey, recovery of the radioactivity required more than ten days.
26. McGinnis, N. A.; Robinson, R. Synthesis of substances related to the sterols. XXXIV. Some thiopyranophenanthrene derivatives. J. Chem. Soc. 1941, 404-408.
27. (R)-3-Butyn-2-ol (ee > 97%) was purchased from DSM Fine Chemicals, 217 Rt. 46W., Saddle Brook, NJ.
28. Chackalamannil, S.; Davies, R. J.; Asberom, T.; Doller, D.; Leone, D. A Highly efficient total synthesis of (+)-himbacine. J. Am. Chem. Soc. 1996, 118, 9812-9813.
29. Four, P.; Guibe, F. Palladium-catalyzed reaction of tributyltin hydride with acyl chlorides. A mild, selective, and general route to aldehydes. J. Org. Chem. 1981, 46, 4439-4445.
30. Wang, X.; Rabbat, P.; O'Shea, P.; Tillyer, R.; Grabowski, E. J. J.; Reider P. J. Selective monolithiation of 2,5-dibromopyridine with butyllithium. Tetrahedron Lett. 2000, 41 (22), 4335-4338.
31. For the use of KF as a base in Suzuki couplings, see: Fu, G. C.; Dai, C.; Littke, A. F. Versatile catalysts for the Suzuki cross-coupling of arylboronic acids with aryl and vinyl halides and triflates under mild conditions. J. Am. Chem. Soc. 2000, 122, 4020-4028 and references cited therein.
32. Ahn, H.-S.; Foster, C.; Boykow, C.; Arik, L.; Smith-Torhan, A.; Hesk, D.; Chatterjee, M. Binding of a thrombin receptor tethered ligand analog to human platelet thrombin receptor. Mol. Pharm. 1997, 51, 350-356.
33. 0-24 hr for (M + 16) metabolites = 2384 ng·hr/ml.
34. Analytical data not shown for 44 and 45.
35. Tritium-labeled 28b was prepared by heating 28b with freshly prepared platinum and tritiated water (530 mCi, 0.9 Ci/mmol) at 110°C for 48 hours. A total batch of 4.9 mCi was isolated after HPLC purification.
36. Eckhardt, H.; Halbritter, K.; Goetz, N.; Heilen, G.; Preparation of 3-formyl-5,6-dihydro-2H-pyran. U.S. Patent 4532337, 1985.
37. Kratzel, M.; Weigl, A. 5-(Alk-l-enyl)-l,2,3,6-tetrahydropyridines as congeners of streptazolin. J. Chem. Soc., Perkin Trans. 1 1997, 1009-1012.